Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Biotechnology

Healthcare
$1.69 -0.90%

-$0.01 today

Market cap
$116.77M
Beta
1.49
P/E (TTM)
-8.9
EPS (TTM)
-$0.12
52W Low $1.03High $2.98

Volume 11.56M

Average 2.73M

INO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Inovio Pharmaceuticals, Inc.NASDAQ: INO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 691.02M shares rose 2444.2% year over year, ahead of the +1040.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 47.4% from the prior quarter. Over 3 fiscal years it compounded at +186.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2444.2% holds above the trailing-twelve-month pace of +1040.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
691.02M+47.4% QoQ
Last fiscal yearDec 2025
468.86M+1626.2% YoY
LTMMar 2026
312.72M+1040.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2444.2%——
1 year+1626.2%——
3-year CAGR+186.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
468.86M USD
Year-over-year change
+1626.2%
4-year CAGR
+21.6%

Weighted Avg Shares vs competitors

How INO compares with its peers on the latest reported figures

  • INO's LTM Mar 2026 weighted avg shares of 312.72M shares is the 2nd highest of the 10 companies compared; the peer median is 56.96M shares.
  • Its year-over-year change of +1040.7% is the 2nd highest of 10, against a peer median of +6.5%.
  • Over three fiscal years its annual growth of +186.8% compares with a peer median of +14.2%.
INO Competitors Peer median
Weighted Avg Shares for INO and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+214.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
SPROSpero Therapeutics, Inc.LTM Mar 202656.4M +3.7%+14.2%
AGENAgenus Inc.LTM Mar 202633.32M +48.8%+28.3%
ACTUActuate Therapeutics IncLTM Mar 202621.96M +12.5%+11.8%
MCRBSeres Therapeutics, Inc.LTM Mar 20268.99M +10.4%+17.9%
Peer median (excluding INO) 56.96M+6.5%+14.2%

Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77M10.26M832.01K217.76K65.34K
Cost of Revenue00000
Gross Profit1.77M10.26M832.01K217.76K65.34K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development249.24M187.65M86.68M75.62M54.21M
Selling, General & Admin53.75M90.19M47.58M37M32.68M
Operating Expenses302.99M277.84M144.77M112.62M86.89M
Depreciation & Amortization4.73M5.5M3.5M3.13M2.99M
EBITDA(296.56M)(270.9M)(130.39M)(103.95M)(81.96M)
EBITDA Margin-16709.7%-2639.8%-15671.8%-47735.2%-125425.9%
Operating Income(301.22M)(267.57M)(143.94M)(112.4M)(86.82M)
Operating Margin-16972.3%-2607.4%-17300.3%-51616.9%-132871.3%
Interest Income3.36M4.78M8.13M4.77M2.42M
Interest Expense1.94M1.25M1.22M177.83K0
Other Income / Expenses(2.44M)(12.24M)8.82M5.14M1.88M
Income Before Tax(303.66M)(279.82M)(135.12M)(107.25M)(84.95M)
Pre-Tax Margin-17109.9%-2726.7%-16239.9%-49254.3%-130000.0%
Income Tax Expense00000
Net Income(303.66M)(279.82M)(135.12M)(107.25M)(84.95M)
Net Margin-17109.9%-2726.7%-16239.9%-49254.3%-130000.0%
EPS (Basic)(1.42)(14.07)(6.09)(3.95)(1.81)
EPS (Diluted)(1.42)(14.07)(6.09)(3.95)(1.81)
Weighted Avg Shares214.62M19.89M22.17M27.16M468.86M
Weighted Avg Shares (Diluted)214.62M19.89M22.17M27.16M468.86M

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Intrinsic Alpha fair value

Locked

Current Price

$1.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.